Abbott (NYSE:ABT) said today that it won FDA approval for a mobile app that is designed for the company’s FreeStyle Libre continuous glucose monitoring system.
The FreeStyle LibreLink app allows users to capture and view their glucose data in real-time using their mobile phones. Prior to the mobile app, people using Abbott’s FreeStyle Libre CGM had to use a separate device to connect data from the sensor to their phones.
Get the full story at our sister site, Drug Delivery Business News.
The post Abbott wins FDA nod for FreeStyle Libre’s mobile app appeared first on MassDevice.
from MassDevice https://ift.tt/2PEuqde
Cap comentari:
Publica un comentari a l'entrada